tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Zenas BioPharma to Present at Jefferies Conference
PremiumCompany AnnouncementsZenas BioPharma to Present at Jefferies Conference
2M ago
Zenas BioPharma Reports Q1 2025 Financial Results
Premium
Company Announcements
Zenas BioPharma Reports Q1 2025 Financial Results
2M ago
Zenas BioPharma’s Promising Autoimmune Pipeline and Obexelimab’s Competitive Edge Drive Buy Rating
Premium
Ratings
Zenas BioPharma’s Promising Autoimmune Pipeline and Obexelimab’s Competitive Edge Drive Buy Rating
2M ago
Zenas BioPharma initiated with an Outperform at Wedbush
PremiumThe FlyZenas BioPharma initiated with an Outperform at Wedbush
4M ago
Zenas BioPharma appoints Lisa von Moltke as Head of R&D, CMO
Premium
The Fly
Zenas BioPharma appoints Lisa von Moltke as Head of R&D, CMO
4M ago
Zenas BioPharma’s Obexelimab: A Promising Therapy with a Buy Rating and $30 Price Target
Premium
Ratings
Zenas BioPharma’s Obexelimab: A Promising Therapy with a Buy Rating and $30 Price Target
5M ago
Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley
PremiumThe FlyZenas BioPharma price target lowered to $35 from $40 at Morgan Stanley
8M ago
Zenas BioPharma reports Q3 EPS ($5.02), consensus ($9.33)
Premium
The Fly
Zenas BioPharma reports Q3 EPS ($5.02), consensus ($9.33)
9M ago
Zenas BioPharma completed targeted enrollment of Phase 3 INDIGO trial
Premium
The Fly
Zenas BioPharma completed targeted enrollment of Phase 3 INDIGO trial
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100